You are here

  • Home
  • Online First
  • Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

Article metrics

Article menu

other Versions

Download PDFPDF
Original research
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

 

Online download statistics by month:

Online download statistics by month: June 2021 to September 2024

AbstractFullPdf
Jun 20211004739
Jul 2021984974306
Aug 2021456444115
Sep 202122421447
Oct 202122914546
Nov 202122812767
Dec 202121615646
Jan 202216911552
Feb 202216511748
Mar 202218016467
Apr 202219014344
May 202217815657
Jun 202219016779
Jul 202222018858
Aug 202225720564
Sep 202223518155
Oct 202243738169
Nov 202219515033
Dec 20221229745
Jan 202311910031
Feb 202316615247
Mar 202311410033
Apr 20231309328
May 2023988916
Jun 20231137422
Jul 20231149725
Aug 202312610630
Sep 20231078831
Oct 2023906924
Nov 2023947017
Dec 20231509630
Jan 2024974115
Feb 2024865142
Mar 202414311945
Apr 20241008336
May 2024917037
Jun 20241067932
Jul 2024926621
Aug 2024977921
Sep 2024463770
Total725459301990